Trial Profile
A retrospective multicentre 12-week study of virologically suppressed HIV-1-infected patients who switched from an unboosted protease inhibitor antiretroviral regimen to a single tablet regimen of rilpivirine/emtricitabine/tenofovir disoproxil fumarate
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Mar 2016
Price :
$35
*
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 02 Mar 2016 New trial record